Pirotinib Hydrochloride

盐酸哌罗替尼

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NamePirotinib Hydrochloride
Drug Alias NameKBP-5209
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShandong Xuanzhu Pharmaceutical Technology Co LtdTianjin Medical University Cancer Institute And Hospital
Inactive CompaniesXuanzhu Pharma Co LtdSihuan Pharmaceutical Holdings Group Ltd
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A